がん分子標的療法ハンドブック

出版社: ヴァンメディカル
著者:
発行日: 2013-06-25
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784860921095
電子書籍版: 2013-06-25
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

3,300 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,300 円(税込)

商品紹介

紙面のほとんどを,各部位のがん(本書では固形癌に限定)に用いる分子標的療法の具体的な選択指針,実際のレジメン,そして有害事象への対応に割き,臨床の場ですぐに役立つ情報を中心に解説した実践的な内容となっています。医師はもちろん,がん診療に携わる全ての医療スタッフ必携の書です。

目次

  • がん分子標的療法ハンドブック

    ―目次―

    I 総論・分子標的治療薬の使用にあたって
     1.分子標的治療薬―これまでの抗がん剤との違い
     2.分子標的治療薬のバイオマーカーと個別化治療
     3.分子標的治療薬はいつ用いるべきか
     4.新規分子標的治療薬への期待

    II 分子標的治療薬を用いた治療の実際
     1.肺がん
     2.胃がん
     3.肝がん
     4.大腸がん
     5.膵がん
     6.乳がん
     7.腎がん
     8.GIST(消化管間質腫瘍:Gastro Intestinal Stromal Tumor)
     9.婦人科がん
     10.頭頸部がん
     11.膵内分泌腫瘍(pNET:pancreatic neuroenrcrine tumor)
     12.その他のがん

    III 分子標的治療薬に特有な有害事象とその対応
     1.骨髄抑制
     2.出 血
     3.血栓塞栓症
     4.皮膚症状/手足症候群
     5.創傷治癒遅延
     6.インフュージョンリアクション
     7.肺障害/間質性肺炎
     8.心機能障害
     9.肝障害
     10.消化管穿孔
     11,高血圧
     12.尿蛋白
     13. 浮 腫
     14.電解質異常

    IV 分子標的治療薬と経済的問題

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論・分子標的治療薬の使用にあたって

P.17 掲載の参考文献
http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted (NCIホームページ : Targeted Cancer Therapies)
P.22 掲載の参考文献
2) Wolff AC, Hammond ME, Schwartz JN et al : American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (1) : 118-145 (2007)
8) Mok TS, Wu YL, Thongprasert S et al : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (10) : 947-957 (2009)
9) Maemondo M, Inoue A, Kobayashi K et al : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 (25) : 2380-2388 (2010)
P.25 掲載の参考文献
http://media.dr-sugahara.net/edgetalk_radio/05-sasaki/01.html (Sugahara Institute website)
P.31 掲載の参考文献

II 分子標的治療薬を用いた治療の実際

P.40 掲載の参考文献
1) Maemondo M, Inoue A, Kobayashi K et al : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 : 2380-2388 (2010)
6) Soda M, Choi YL, Enomoto M et al : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. ture 448 : 561-566 (2007)
http://www.haigan.gr.jp/modules/guideline/index.php?content_id-3 (日本肺癌学会 肺癌診療ガイドライン)
P.46 掲載の参考文献
2) Koizumi W, Narahara H, Hara T et al : S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol 9 (3) : 215-221 (2008)
4) Van Cutsem E, Yeh KH, Bang Y et al : Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC) : GRANITE-1. Gastrointestinal Cancers Symposium (2012)
5) Bang Y, Chung H, Sawaki A et al : HER2-positivity rates in advanced gastric cancer (GC) : Results from a large international phase III trial. ASCO Annual Meeting (2008)
6) Yano T, Doi T, Ohtsu A et al : Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15 (1) : 65-71 (2006)
7) Terashima M, Ochiai A, Kitada K et al : Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. ASCO Annual Meeting (2008)
http://chugai-pharm.jp/hc/ss/pa/sf/her/index.html (中外製薬株式会社・ハーセプチン患者用サイト)
P.55 掲載の参考文献
1) 日本肝臓学会編 : 肝癌診療マニュアル 第2版. 医学書院, 東京 (2010) p. 125
5) ネクサバール特定使用成績調査 (全例調査) 第2回中間報告書 PDFダウンロード (3.2MB). http://www.nexavar.jp/unmember/pdf/hcc201205.pdf (2012. 6. 19アクセス)
・ http://www.jsh.or.jp/medical/kangan-gl.html (肝がん治療サイトURL日本肝臓学会 肝癌診療ガイドライン 2009年版)
・ http://www.nexavar.jp/unmember/nex_kijo01.html (バイエル薬品株式会社 Naxavar)
P.69 掲載の参考文献
1) Hurwitz H et al : N Engl J Med 350 : 2335-2342 (2004)
2) Cassidy J et al : J Clin Oncol 26 (12) : 2006-2012 (2008)
6) Folprecht G et al : Lancet Oncol 11 (1) : 38-47 (2010)
7) Van Cutsem E et al : J Clin Oncol 25 (13) : 1658-1664 (2007)
http://www.gsic.jp/cancer/cc_15/lic06/index.html (がんサポート情報センター)
P.75 掲載の参考文献
2) Moore MJ et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15) : 1960-1966 (2007)
3) Burris HA 3rd et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 15 (6) : 2403-2413 (1997)
6) Ioka T et al : Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan : GEST study. J Cline Oncol 29 : 2011 (suppl ; abstr 4007)
7) Conroy T et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine 364 (19) : 1817-1825 (2011)
8) Von HoffDD et al : Randomized phase III study of weekly nab-paclitaxel plus gemcitabime alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 30 : 2012 (suppl 34 ; abstr LBA 148)
http://www.nccn.org/proffessionals/physician_gls/pdf/pancreatic.pdf (National Comprehensive Cancer Network)
P.82 掲載の参考文献
P.86 掲載の参考文献
1) Slamon DJ et al : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer overexpresses HER2. N Engl J Med 344 : 783-792 (2001)
3) von Minckwitz G et al : Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer : A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 27 : 1999-2006 (2009)
4) Blackwell KL et al : Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer : Final Results From the EGF 104900 Study. J Clin Oncol 30 : 2585-2592 (2012)
7) Swain SM et al : Confirmatory overall survival (OS) analysis of CLEOPATRA : a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (IL) metastatic breast cancer (MBC). 2012 CTRC-AACR San Antonio Breast Cancer Symposium. Abstract #. P 5-18-26
12) Joensuu H et al : Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer : final results of the Fin Her Trial. J Clin Oncol 27 : 5685-5692 (2009)
14) Goldhirsch A et al : HERA TRIAL : 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. 2012 CTRC-AACR San Antonio Breast Cancer Symposium. Abstract #. S5-2.
15) Pivot X et al : PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. 2012 CTRC-AACR San Antonio Breast Cancer Symposium. Abstract #. S5-3.
20) Robert NJ et al : RIBBON-1 : randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29 : 1252-1260 (2011)
21) Gianni L et al : AVEREL : A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab as First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. J Clin Oncol (2013) [Epub ahead of print]
http://www.jccnb.net/guideline/index.html (日本乳がん情報ネットワーク : NCCNガイドライン 翻訳一覧)
P.99 掲載の参考文献
1) Naito S et al : Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era : a cooperative group report of 1463 patients. Eur Urol 57 : 317-325 (2010)
3) 日本泌尿器科学会編 : CQ 7 ; 転移性腎癌の予後予測因子による治療法選択は推奨されるか? 腎癌診療ガイドライン 2011年版. 金原出版, 東京 (2011) pp25-27
6) Hudes G et al : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 : 2271-2281 (2007)
7) Hudes G et al : NCCN task force report : Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 9 (suppl) : S1-27 (2011)
16) Rini BI et al : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) : a randomised phase 3 trial. Lancet 378 (9807) : 1931-1939 (2011)
http://www.uroweb.org/gls/pdf/NEW09_Renal_Cell-Carcinoma_LR.pdf (欧州泌尿器科学会・腎細胞がん治療ガイドライン)
P.109 掲載の参考文献
1) Demetri GD : Efficacy and safety of imatinib mesylate in advanced gastroin-testinal stromal tumors. N Engl J Med 347 (7) : 472-480 (2002)
3) Patrikidou A, Blay JY, Le Cesne A et al : Influence of imatinib interruption and rechallenge on the residual diseasein patients with advanced GIST : results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. French Sarcoma Group. Ann Oncol 24 (4) : 1087-1093 (2013)
8) Demetri GD, Reichardt P, Kang YK et al : Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. Nov 21. (2012) (2012)
http://www.gist.jp/ (GIST研究会ホームページ)
P.119 掲載の参考文献
2) du Bois A, Luck HJ, Meier W et al : A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 : 1320-1329 (2003)
4) Parmar MK, Ledermann JA, Colombo Net al : ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer : the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (9375) : 2099-2106 (2003)
7) Boss EA, Massuger LF, Thomas CM et al : Vascular endothelial growth factor in ovarian cyst fluid. Cancer 91 : 371-377 (2001)
9) Zebrowski BK, Liu W, Ramirez K et al : Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6 : 373-378 (1999)
13) Aghajanian C, Finkler NJ, Rutherford, T. OCEANS : A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacitumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 29 ASCO MEETING ABSTRACTS LBA5007 (2001)
14) Pujade-Lauraine E, Hilpert F, Weber B et al : AURELIA : A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT) -resistant recurrent ovarian cancer (OC). J Clin Oncol 30 ASCO MEETING ABSTRACTS May 30, 2012 : LBA5002 (2012)
17) Matulonis UA, Berlin S, Ivy P et al : Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27 : 5601-5606 (2009)
18) Hoffman-La Roche Limited. AVASTIN(R) product monograph. Mississauga, Ontario ; 26 August 2010.
22) Rudd ML, Price JC, Fogoros S et al : Aunique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 17 (6) : 1331-1340 (2011)
24) Slomovitz BM, Lu KH, Johnston T et al : A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116 (23) : 5415-5419 (2010)
25) Slomovitz BM, Brown J, Johnston TA, et al : A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 29 : (2011) ASCO MEETING ABSTRACTS : LBA5012.
27) Monk BJ, Sill MW, Burger RA et al : Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix : a gynecologic oncology group study. J Clin Oncol 27 (7) : 1069-1074 (2009)
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (NCCNガイドラインの「ovarian cancer」【要登録】)
P.131 掲載の参考文献
1) Ang KK et al : Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 : 7350-7356 (2002)
2) Arlene A et al : Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N Engl J Med 349 : 2091-2098 (2003)
4) Pignon JP et al : Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma : three meta-analyses of updated individual data. The Lancet 355 (9208) : 949-955 (2000)
5) Browman GP et al : Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer : A systematic review of the published literature with subgroup analysis Head & Neck 23 (Issue 7) : 579-589 (2001)
7) Ang KK, Zhang QE, Rosenthal DI et al : A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29 : abstr 5500 (2011)
8) http://clinicaltrials.gov/ct2/show/NCT01302834.
10) Ma BBY et al : A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma Ann Oncol (2011) First published online : September 23 (2011)
11) Chan ATG : Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma JCO 23 (15) : 3568-3576 (2005)
13) Harari PM et al : Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG0234) International Journal of Radiation Oncology* Biology* Physics 69 (3) : S13 (2007)
14) http://clinicaltrials.gov/ct2/show/NCT01311063?term=RTOG0920&rank=1
19) Ezra EWC et al : DeCIDE : A phase III rendomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 loccally advanced squamous cell carcinoma of the head and neck (SCCHN). JCO 30, 2012 (suppl abstr 5500)
20) Haddad RI et al : Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM) : a randomised phase 3 trial The Lancet Oncology 14 (3) : 257-264 (2013) Early Online Publication, 13 February 2013 doi : 10.1016/S1470-2045 (13) 70011-1
22) Merrill SK et al : Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck : Results From a Phase II Prospective Trial. JCO 28 (1) : 8-14 (2010)
23) Argiris A et al : "Induction docetaxel, Cisplatin and Cetuximab tollowed by concurrent radio therapy, cisplatin and cetuximab and maintonance cetuximab in patients with loccaly advanced head and neck cancer" JCO vol 28 no 36 5294-5300
・ http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (NCCNガイドラインの「Head and Neck Cancer」【要登録】)
・ http://www.chemoregimen.com/ (chemoregimen. com)
P.135 掲載の参考文献
2) Ito T, Okusaka T : Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs (2012)
P.137 掲載の参考文献

III 分子標的治療薬に特有な有害事象とその対応

P.142 掲載の参考文献
3) O'Brien SG, Guilhot F et al : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (11) : 994-1004 (2003)
6) Smith TJ et al : American Society of Clinical Oncology (2006) Update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205 (2006)
7) NCCNガイドライン, Prevention and Treatment of Cancer-Related Infections : http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
8) NCCNガイドライン, Myeloid Growth Factors : http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf
9) NCCNガイドライン, Cancer-and Chemotherapy-Induced Anemia : http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf
11) Smith TJ et al : American Society of Clinical Oncology (2006) Update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205 (2006)
・ http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site (NCCNガイドライン【要登録】)
・ http://www.mhlw.go.jp/topics/2006/11/tp1122-1.html (厚生労働省 重篤副作用疾患別対応マニュアル)
・ http://ganjoho.jp/public/dia_tre/attention/chemotherapy/side_effect/index.html (独立行政法人国立がん研究センターがん対策情報センター【患者向け】)
P.147 掲載の参考文献
・ http://www.mhlw.go.jp/topics/2006/11/tp1122-1.html (厚生労働省 重篤副作用疾患別対応マニュアル)
・ http://ganjoho.jp/public/support/condition/hemorrhage.html (独立行政法人国立がん研究センターがん対策情報センター【患者向け】)
P.150 掲載の参考文献
3) Barnard K et al : Viewpoint : an explanation for the cardiovascular effects of bevacizumab and rofecoxib? Circulation 114 : f173-175 (2006)
4) Geiger-Gritsch et al : Safety of bevacizumab in patients with advanced cancer : a meta-analysis of randornized controlled trials. The Oncologist 15 : 1170-1191 (2010)
7) 安藤太三ほか : 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン. Circulation Journal 68 : 1079-1152 (2004)
8) Lyman GH et al : American Society of Clinical Oncology Guideline : recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 : 5490-5505 (2007)
http://www.pmda.go.jp/ (独立行政法人医薬品医療機器総合機構ホームページ)
P.154 掲載の参考文献
1) Valeyrie L et al : Adverse cutaneous reactions to imatinib (ST571) in Philaderphia chromosome-positive leukemia : a prospective study of 54 patients. J Am Acad Dermatol 48 : 201-206 (2003)
3) Lee WJ et al : Cutaneous adverse effects in patients treated with the multi-targeted kinase inhibitors sorafenib and sunitnib. Br J Dermatol 161 : 1045-1051 (2009)
4) ファイザー社 HP : https://pfizerpro.jp/download.php?key=2tzkbsYvyq3igRpjW6pxYw==
5) Grothy A : Patient with colorectal cancer treated with regorafenib or placebo after failure of Standerd therapy (2012 ASCO-GI)
6) 村田壱大ほか : 腎細胞癌の分了標的薬治療におけるhand-foot syndrome. 皮膚病診療 32 : 883-886 (2010)
8) Sceithauer W et al : Oral capecitabine as an alternative to i. v. 5-fluorouracil-based adjuvant therapy for colon cancer : safety results of randomized phase III trial. Ann Oncol 14 : 1735-1743 (2003)
9) Lazouture ME et al : Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28 : 1351-1357 (2010)
http://www.pmda.go.jp/ (独立行政法人医薬品医療機器総合機構ホームページ)
P.158 掲載の参考文献
1) Faif MW : Managing Bevacizumab-Related Toxicities in Patients with Colorectal Cancer. The Journal of Supportive Oncology 7 (6) : 245-51 (2009)
http://www.bccancer.bc.ca/NR/rdonlyres/6D39414F-EC1A-4BE2-9ACB-6DE017C9B4C4/19258/Managementforbevacizumabsideeffects_1Dec06.pdf#search='Bevacizumab+guidelines+BC+Cancer+Agency' (Management Guidelines for Bevacizumab)
P.161 掲載の参考文献
1) ハーセプチン適正使用ガイド
・ http://www.cancertherapy.jp (大鵬薬品工業株式会社ホームページ)
・ http://www.uptodate.com (Up To Date社ホームーページ)
P.165 掲載の参考文献
1) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会編 : 薬剤性肺障害の診断・治療の手引き. メディカルレビュー社 (2012)
http://www.pmda.go.jp/ (医薬品情報データベース : 独立行政法人医薬品医療機器総合機構ホームページ)
P.169 掲載の参考文献
・ http://www.cancertherapy.jp/sideeffect_manual/2009_autumn/03.html (Cancer Therapy. jp コンセンサス癌治療)
・ http://www.anticancer-drug.net/ (抗がん剤の種類と副作用)
P.173 掲載の参考文献
3) 坪内博仁ほか : 免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-肝臓 50 : 38-42 (2009)
・ http://www.info.pmda.go.jp/juutoku/file/jfm0804002.pdf (独立行政法人医薬品医療機器総合機構ホームページ, 重篤副作用疾患別対応マニュアル薬物性肝障害)
・ http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf (Guidance for Industry Drug-Induced Liver Injury : Premarketing Clinical Evaluation)
P.175 掲載の参考文献
1) Sanjaykumar H et al : Lancet Oncol 10 : 559-568 (2009)
2) Fairooz FK et al : Eur J Cancer 48 : 1126-1132 (2012)
http://chugai-pharm.jp/hc/ss/pr/tl/ic/index.html (中外製薬株式会社ホームページ)
P.178 掲載の参考文献
2) Josep M et al : Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 24 : 378-390 (2008)
3) Grothy A : Patient with colorectal cancer treated with regorafenib or placebo after tailure of Standerd therapy (2012 ASCO-GI)
4) Kabbinavar F et al : Guidelines for the management of side effects of bevacizumab in patients with colorectal cancer. Cancer Therapy 6 : 327-340 (2008)
http://www.gsic.jp/ (がんサポート情報センターホームページ)
P.181 掲載の参考文献
1) Clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kid Dis 39 (Supple 1) : S1-S266 (2002)
2) Hassane I et al : VEGF signalling inhibition-induced proteinuria : Mechanisms, significance and management. Eur J Cancer 46 : 439-448 (2010)
http://www.gsic.jp/ (がんサポート情報センターホームページ)
P.183 掲載の参考文献
1) グリベック(R) カプセル100mg市販直後調査の副作用集計 (GIST)
2) NCCN Task Force report : management of patients with gastrointestinal stromal tumor (GIST) -update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 Suppl 2) : S1-29 ; quiz S30 (2007)
3) GIST研究会編 : GISTの診断と治療 実践マニュアル, エルゼビア・ジャパン (2006)
4) Druker BJ et al : Hematology 1 : 87-112 (2001)
・ http://www.gist.jp (GIST研究会一般向けページ)
・ http://clinicalpath.jp (大鵬薬品工業株式会社・クリニカルパス情報ページ)
・ http://www.jcog.jp/doctor/tool/CTCAEv4J_20111217.pdf (JCOGホームページ, CTCAE日本語訳ページ)
P.188 掲載の参考文献
http://www.cancertherapy.jp/emergency_manual/2010_winter/01_08.html (大鵬薬品工業株式会社・コンセンサス癌治療ホームページ)

IV 分子標的治療薬と経済的問題

P.192 掲載の参考文献
・ http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/juuyou/kougakuiryou/index.html (厚生労働省 > 高額療養費制度を利用される皆さまへ)
・ http://www.kyoukaikenpo.or.jp/ (全国健康保険協会)
・ http://ganjoho.jp/public/support/backup/cost.html (国立がん研究センターがん対策情報センター がん情報サービス > 治療にかかる費用とその支援)

最近チェックした商品履歴

Loading...